A FEARLESS EMBRACE of POTENTIAL

We are developing highly engineered, targeted therapies for patients fighting serious liver diseases

 
web-banner-home2.jpg
 

Unlocking the value of life-improving medicines

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing highly engineered therapies to transform the lives of patients who fight serious liver diseases.

 

Innovative collaborations and evidence-based decision making are core to our ways of working

We have partnered with biotechnology and pharmaceutical companies to acquire innovative drug candidates. We employ unencumbered decision making and advance only those programs that meet our stringent development hurdles.

 
 
 
 

A Path to Value for Our Partners and Patients

We have established partnerships with the world’s leading biotechnology and pharmaceutical companies. We continue to seek new ways to leverage our model and create a path to value for our partners and patients across serious liver diseases.

 
jacob-licht-8nA_iHrxHIo-unsplash.jpg
 
 

Recent News

07/07/2025

GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

05/14/2025

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

04/28/2025

Boston Pharmaceuticals to Present the Effect of Efimosfermin Alfa on Collagen Biomarkers in Patients with F2 and F3 MASH at EASL Congress 2025

04/23/2025

Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week® 2025

11/15/2024

Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting®

10/16/2024

Boston Pharmaceuticals to Present Phase 2 Biopsy Results for Long-Acting, Once-Monthly FGF21 Analogue Efimosfermin Alfa (BOS-580) in F2 and F3 MASH in Late-Breaking Oral Presentation at AASLD, The Liver Meeting® 2024

You are now leaving the Boston Pharmaceuticals page,
and will be redirected to gsk.com.

 
 
 

We attribute our success in our pipeline to the exceptional people working at Boston Pharmaceuticals. We embrace the development of our employees and seek passionate, science-driven candidates with an intellectual curiosity for more.